top of page
iPharmaCenter
News | Blogs | Healthcare | Consulting
Contact:
info@ipharmacenter.com
Home
Pharma
North America
US FDA Approvals
Canada Drug Healthcare News
APAC
China Drug Approvals
India Drug Approvals
APAC - Drug Approvals
Japan Drug Approvals | Healthcare
Europe
EMA News
LACAM
Brazil - Drug approvals
Healthcare News
US Healthcare News
US Payer News
APAC - Healthcare News
Europe Healthcare News
Lacam Healthcare News
Healthcare Policies
Disease News
Immunology
Oncology
Infections_Vaccines
Cardiovascular
Kidney Diseases
Metabolic Diseases
Women Health
Neurology
Conferences
Others
COVID-19
Contact
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Log in / Sign up
Top Drug Launches to Watch in 2025 | iPharmaCenter
ipharmaservices
Feb 16
Novartis Strengthens Cardiovascular Portfolio with $3.1 Billion Anthos Therapeutics Acquisition | iPharmaCenter
ipharmaservices
Feb 11
Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter
ipharmaservices
Feb 6
AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter
ipharmaservices
Feb 3
European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter
ipharmaservices
Feb 3
Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter
ipharmaservices
Feb 2
Roche’s Itovebi Combination Therapy Shows Significant Survival Benefit in Advanced PIK3CA-mutated, HR-positive, HER2-negative Breast Cancer | iPharmaCenter
ipharmaservices
Jan 29
American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium | iPharmaCenter
ipharmaservices
Jan 25
Sarclisa Receives EU Approval as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant
ipharmaservices
Jan 25
Novo Nordisk Unveils Promising Higher-Dose Semaglutide Results for Obesity After CagriSema Setback | iPharmaCenter
ipharmaservices
Jan 23
AbbVie and Simcere Zaiming Collaborate to Develop Innovative Treatment for Multiple Myeloma | iPharmaCenter
ipharmaservices
Jan 21
FDA Approves Omvoh for Crohn’s Disease, Expanding Its Reach in Inflammatory Bowel Disease Treatment | iPharmaCenter
ipharmaservices
Jan 21
Johnson & Johnson Expands Neuroscience Portfolio with Acquisition of Intra-Cellular Therapies | iPharmaCenter
ipharmaservices
Jan 21
J.P. Morgan Healthcare Conference 2025 | Novartis | Merck | News | Updates
ipharmaservices
Jan 18
Sanofi Reports Positive Results for Subcutaneous Sarclisa, Aiming to Strengthen Competition with Darzalex | iPharmaCenter
ipharmaservices
Jan 9
Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter
ipharmaservices
Jan 9
Valo Health and Novo Nordisk Expand Partnership to Develop Treatments for Cardiometabolic Diseases | iPharmaCenter
ipharmaservices
Jan 8
Novartis aims to treat broader patient population with intrathecal onasemnogene abeparvovec | iPharmaCenter
ipharmaservices
Jan 2
Expected best selling drugs of 2025 | Top pharmaceuticals by revenues | iPharmaCenter
ipharmaservices
Jan 1
Bristol Myers Squibb Reports Positive Results from Phase 3 Trials of Deucravacitinib in Psoriatic Arthritis | iPharmaCenter
ipharmaservices
Dec 27, 2024
bottom of page
